|
ATE303160T1
(de)
*
|
1993-08-11 |
2005-09-15 |
Jenner Technologies |
Impfstoff gegen prostatakrebs
|
|
US20010036928A1
(en)
*
|
1996-04-22 |
2001-11-01 |
Chamberlain Ronald S. |
Heterologous boosting immunizations
|
|
US6969609B1
(en)
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
GB2347932B
(en)
*
|
1998-11-18 |
2003-05-07 |
Oxford Biomedica Ltd |
Vectors for the delivery of 5T4 antigen
|
|
US7148035B1
(en)
|
1998-11-18 |
2006-12-12 |
Oxford Biomedica (Uk) Limited |
Polypeptide
|
|
AU774076C
(en)
*
|
1998-12-09 |
2005-04-14 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
A recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
EP1865065A1
(en)
*
|
1998-12-09 |
2007-12-12 |
The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services |
A recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
US7786278B2
(en)
*
|
2002-04-09 |
2010-08-31 |
Sanofi Pasteur Limited |
Modified CEA nucleic acid and expression vectors
|
|
NZ545438A
(en)
*
|
2003-08-21 |
2008-08-29 |
Virax Dev Pty Ltd |
Poxvirus vector encoding prostate specific antigens for treatment of prostate cancer
|
|
CN101124327A
(zh)
*
|
2003-10-08 |
2008-02-13 |
圣诺菲·帕斯图尔公司 |
经修饰的cea/b7载体
|
|
US8901093B2
(en)
|
2003-11-12 |
2014-12-02 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Custom vectors for treating and preventing pancreatic cancer
|
|
US8933041B2
(en)
|
2003-11-12 |
2015-01-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
System for treating and preventing breast cancer
|
|
KR20110117654A
(ko)
|
2009-01-13 |
2011-10-27 |
트랜스진 에스.에이. |
면역 자극에 있어서의 사카로미세스 세레비지아에 미토콘드리아 핵산 분획물의 용도
|
|
PT2382474E
(pt)
|
2009-01-20 |
2015-06-03 |
Transgene Sa |
Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica
|
|
CA2756133A1
(en)
|
2009-03-24 |
2010-09-30 |
Transgene S.A. |
Biomarker for monitoring cancer patients
|
|
JP5661738B2
(ja)
|
2009-04-17 |
2015-01-28 |
トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． |
患者をモニターするためのバイオマーカー
|
|
PH12011502635A1
(en)
|
2009-07-10 |
2012-11-12 |
Transgene Sa |
Biomarker for selecting patients and related methods
|
|
AU2011285534B2
(en)
|
2010-08-06 |
2015-12-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarkers for prostate cancer and methods for their detection
|
|
US9725494B2
(en)
*
|
2013-05-17 |
2017-08-08 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Soluble CD27 (sCD27) and the use thereof
|
|
AU2014347004B2
(en)
*
|
2013-11-05 |
2019-08-08 |
Bavarian Nordic A/S |
Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist and/or agonist of an immune checkpoint inhibitor
|
|
JP2017515841A
(ja)
|
2014-05-13 |
2017-06-15 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法
|
|
CA2955084C
(en)
|
2014-07-16 |
2023-08-29 |
Transgene Sa |
Combination of oncolytic virus with immune checkpoint modulators
|
|
WO2016128542A1
(en)
|
2015-02-13 |
2016-08-18 |
Transgene Sa |
Immunotherapeutic vaccine and antibody combination therapy
|
|
CN107922981B
(zh)
|
2015-07-31 |
2022-02-25 |
巴法里安诺迪克有限公司 |
用于增强在痘病毒中的表达的启动子
|
|
WO2017120204A2
(en)
|
2016-01-05 |
2017-07-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination of histone deacetylase inhibitor and immunotherapy
|
|
ES2924741T3
(es)
|
2016-01-28 |
2022-10-10 |
Inst Nat Sante Rech Med |
Métodos para incrementar la potencia de los inhibidores del punto de control inmunitario
|
|
WO2017136342A1
(en)
|
2016-02-02 |
2017-08-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fulvestrant for inducing immune-mediated cytotoxic lysis of cancer cells
|
|
EP3452081A1
(en)
|
2016-05-04 |
2019-03-13 |
Transgene SA |
Combination therapy with cpg tlr9 ligand
|
|
US11052139B2
(en)
|
2016-09-28 |
2021-07-06 |
Bavarian Nordic A/S |
Compositions and methods for enhancing the stability of transgenes in poxviruses
|
|
WO2018069316A2
(en)
|
2016-10-10 |
2018-04-19 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
WO2018091680A1
(en)
|
2016-11-18 |
2018-05-24 |
Transgene Sa |
Cowpox-based oncolytic vectors
|
|
CN110168092A
(zh)
|
2016-12-28 |
2019-08-23 |
特朗斯吉有限公司 |
溶瘤病毒和治疗分子
|
|
EP3610022A1
(en)
|
2017-04-14 |
2020-02-19 |
Tollnine, Inc. |
Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
|
|
CN110769850A
(zh)
|
2017-05-15 |
2020-02-07 |
扬森疫苗与预防公司 |
稳定的含病毒组合物
|
|
CN110603058A
(zh)
|
2017-05-15 |
2019-12-20 |
扬森疫苗与预防公司 |
含有病毒的稳定组合物
|
|
WO2019020543A1
(en)
|
2017-07-28 |
2019-01-31 |
Transgene Sa |
ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
|
|
WO2019038388A1
(en)
|
2017-08-24 |
2019-02-28 |
Bavarian Nordic A/S |
POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY
|
|
US12377142B2
(en)
|
2018-03-07 |
2025-08-05 |
Transgene |
Recombinant pseudocowpoxvirus
|
|
WO2020011754A1
(en)
|
2018-07-09 |
2020-01-16 |
Transgene |
Chimeric vaccinia viruses
|
|
CA3111273C
(en)
|
2018-09-06 |
2024-03-26 |
Bavarian Nordic A/S |
Storage improved poxvirus compositions
|
|
US20220233607A1
(en)
|
2019-05-29 |
2022-07-28 |
Université De Tours |
Toxoplasma platform for treating cancer
|
|
IL295759A
(en)
|
2020-02-28 |
2022-10-01 |
Tallac Therapeutics Inc |
Transglutaminase mediated coupling
|
|
KR20220153587A
(ko)
|
2020-03-12 |
2022-11-18 |
버베리안 노딕 에이/에스 |
폭스바이러스 안정성을 개선하는 조성물
|
|
AU2023326730A1
(en)
|
2022-08-18 |
2025-03-13 |
Transgene |
Chimeric poxviruses
|